Exhibit 99
                                  8

                                                             James H. Miller
                                                             President and CEO
                                                                   and
                                                             Jeffrey W. Church
                                                             Sr. Vice President
                                                             Finance and CFO
                                                             1-800-638-8093

FOR IMMEDIATE RELEASE
        STI ANNOUNCES AGREEMENT FOR SALE OF ESTATE STOCK

ROCKVILLE, Maryland, March 19, 1996--Survival Technology, Inc. (STI) 
(NASDAQ:STIQ) today announced that the Estate of Stanley J. Sarnoff, the 
late founder of the company, has entered into an agreement with Brunswick 
Biomedical Corporation (BBC), a privately held medical device company, for 
the purchase of the STI shares held by the Sarnoff estate.  The Sarnoff 
estate currently holds approximately 61 percent of the company's outstanding 
stock.  Closing is anticipated in the coming weeks.

The STI Board has approved the proposed transaction representing a 
culmination of a process which began two years ago when the Sarnoff estate 
indicated its desire to explore liquidation of its holdings.  In connection 
with STI board approval, BBC has agreed to various measures designed to 
protect the interests of STI minority shareholders.

Brunswick Biomedical, which has had a close working relationship with STI for 
many years, said it plans to merge its administrative functions into STI, 
which will continue to operate as in the past, and thereafter seek a 
combination of the two companies.

Brunswick Biomedical develops, manufactures and markets products used in 
emergency medical services for cardiac patients.

STI is a technology-based health care company that designs, develops and 
produces automatic injectors, with a major focus on safe and convenient 
participation by the patient in injection therapy.  The company also supplies 
customized drug delivery system design, pharmaceutical research and 
development, and GMP-approved sterile product manufacturing to pharmaceutical 
and biotechnology companies.  The company's products and services are 
designed to improve the medical and economic value of drug therapy.


                                       #